Bryan Black develops human iPSC-derived neural tissue models and microelectrode-based electrophysiology platforms to quantify network function and glia-neuron interactions, enabling phenotypic screening and target validation for non-addictive analgesics, radioprotectants, and neuroactive therapeutics.